39
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Investigation on a New Modified USP Xanthan with Tablet-Disintegrating Properties

, , &
Pages 19-26 | Published online: 20 Oct 2008

References

  • Ringard J., Guyot-Hermann A.-M. Calculation of disintegrant critical concentration in order to optimize tablets disintegration. Drug Dev. Ind. Pharm. 1988; 14(15–17)2321
  • Rizk S., Duru C., Gaudy D., Jacob M., Ferrari F., Bertoni M., Caramella C. Physico-chemical characterization and tabletting properties of Scleroglucan. Int. J. Pharm. 1994; 112: 125
  • Duru C., Gaudy D., Neye H., Rizk S., Jacob M., Puech A. A new tablet disintegrating agent. Xanthan SM: Formulation and drug release study, Die Pharmazie 1995; 50: 272
  • Lefebvre C., Guillaume F., Bouché R., Bouaziz R., Guyot J.-C. Etude des différentes formes polymorphiques du méprobamate. Pharma. Acta Helv. 1992; 66(3)90
  • Bleuse B., Marais B., Lefrant A., Delacourte A., Guyot J.-C. Utilisation d'un système informatique pour la formulation technologique des comprimés. ITBM 1982; 3(2)211
  • Guyot J.-C., Delacourte A., Leterme P., Billardon P. Utilisation des chaînes de mesure et de plans d'expérience dans la recherche et le développement des comprimés. STP Pharma. 1989; 5(3)168
  • Guyot J.-C., Tete L., Tak Tak S., Delacourte A. Practical interest of the cohesion index for the technological formulation of tablets, 6ème Congrès. International de Technologie Pharmaceutique. 1992; Vol. 3: 246

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.